Jin Rong Jie·2025-08-05 08:53Group 1 - The Shanghai Composite Index rose by 0.96% to close at 3617.6 points, while the Hang Seng Index increased by 0.68% to 24902.53 points [1] - Fudan Zhangjiang's A/H premium reached 177.33%, ranking fourth among A/H shares [1] - Fudan Zhangjiang's A-shares closed at 10.92 yuan, down 0.27%, and H-shares closed at 4.3 HKD, up 1.65% [1] Group 2 - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a knowledge-based innovation enterprise [1] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic technology drugs, nanotechnology drugs, and oral solid dosage technology drugs, with new products expected to be launched in the market [1]